Mercury Biopharmaceutical Receivables

Mercury Biopharmaceutical's receivables stands at $300K as of June 2026. That compares with $450K in the prior-year period — down 33.6% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Mercury Biopharmaceutical reported $300K in receivables versus $450K a year earlier — a 33.6% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $450K in the prior-year period — down 33.6% year over year. Sustained growth in receivables can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Mercury Biopharmaceutical's receivables evolved across reporting periods, while the comparison chart places 6932.TWO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.